Negara: Irlandia
Bahasa: Inggris
Sumber: HPRA (Health Products Regulatory Authority)
CARBOPLATIN
Amneal Pharma Europe Limited
CARBOPLATIN
10 Mg/Ml
Concentrate for Soln for Inf
Product subject to prescription which may not be renewed (A)
Withdrawn
2013-10-31
1 PACKAGE LEAFLET: INFORMATION FOR THE USER CARBOPLATIN 10 MG/ML CONCENTRATE FOR SOLUTION FOR INFUSION _ _ carboplatin READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START USING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. - Keep this leaflet. You may need to read it again. - If you have any further questions, ask your doctor or nurse. - If you get any side effects, talk to your doctor or nurse. This includes any possible side effects not listed in this leaflet. See section 4. WHAT IS IN THIS LEAFLET 1. What Carboplatin is and what it is used for 2. What you need to know before you are given Carboplatin 3. How you are given Carboplatin 4. Possible side effects 5. How to store Carboplatin 6. Contents of the pack and other information 1. WHAT CARBOPLATIN IS AND WHAT IT IS USED FOR Carboplatin concentrate contains the active ingredient carboplatin which belongs to a group of medicines known as platinum coordination compounds, which is used to treat cancer. Carboplatin is used against advanced cancer of the ovary and small cell cancer of the lung. 2. WHAT YOU NEED TO KNOW BEFORE YOU ARE GIVEN CARBOPLATIN DO NOT USE CARBOPLATIN: if you are allergic to carboplatin or any of the other ingredients of this medicine (listed in section 6). if you are allergic to another drug that belongs to the group of platinum containing compound. if you are breast feeding. if you have severe problems with your kidney (creatinine clearance below 30 ml/min) and/or liver fuinction. if you have an imbalance of your blood cells (severe myelosuppression). if you have a tumour that bleeds. If you plan to receive a yellow fever vacci Baca dokumen lengkapnya
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Carboplatin 10 mg/ml concentrate for solution for infusion 2 QUALITATIVE AND QUANTITATIVE COMPOSITION 1 ml of concentrate for solution for infusion contains 10 mg of carboplatin. One vial of 5 ml contains 50 mg carboplatin. One vial of 15 ml contains 150 mg carboplatin. One vial of 45 ml contains 450 mg carboplatin. One vial of 60 ml contains 600 mg carboplatin. One vial of 100 ml contains 1000 mg carboplatin. For the full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Concentrate for solution for infusion. Carboplatin is a clear, colourless to pale yellow solution free from particles. pH: 5.0 – 7.0 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Carboplatin is indicated for the treatment of: Advanced ovarian carcinoma of epithelial origin in: o First line therapy o Second line therapy, after other treatments have failed. Small cell carcinoma of the lung. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Posology Carboplatin should be used by the intravenous route only. The recommended dosage of carboplatin in previously untreated adult patients with normal kidney function, i.e. with creatinine clearance > 60 ml/min is 400 mg/m 2 as a single intravenous dose administered by a 15 to 60 minute infusion. Alternatively, the Calvert formula shown below may be used to determine dosage: Dose (mg) = target AUC (mg/ml x min) x [GFR ml/min + 25] DOSE (MG) = TARGET AUC (MG/ML X MIN) X [GFR ML/MIN + 25] TARGET AUC PLANNED CHEMOTHERAPY PATIENT TREATMENT STATUS 5 – 7 mg/ml.min Single agent carboplatin Previously untreated 4 – 6 mg/ml.min Single agent carboplatin Previously treated 4 – 6 mg/ml.min Carboplatin plus cyclophosphamide Previously untreated IRISH MEDICINES BOARD ______________________________________________ Baca dokumen lengkapnya